231 related articles for article (PubMed ID: 38705930)
1. Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
Gou Q; Gou Q; Gan X; Xie Y
Sci Rep; 2024 May; 14(1):10317. PubMed ID: 38705930
[TBL] [Abstract][Full Text] [Related]
2. The impact of genomic changes on treatment of lung cancer.
Cardarella S; Johnson BE
Am J Respir Crit Care Med; 2013 Oct; 188(7):770-5. PubMed ID: 23841470
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for lung cancer: Beyond EGFR and ALK.
Herrera-Juárez M; Serrano-Gómez C; Bote-de-Cabo H; Paz-Ares L
Cancer; 2023 Jun; 129(12):1803-1820. PubMed ID: 37073562
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MET gene for the treatment of non-small-cell lung cancer.
Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
[TBL] [Abstract][Full Text] [Related]
5. Current drugs and drug targets in non-small cell lung cancer: limitations and opportunities.
Daga A; Ansari A; Patel S; Mirza S; Rawal R; Umrania V
Asian Pac J Cancer Prev; 2015; 16(10):4147-56. PubMed ID: 26028064
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
Qin K; Hou H; Liang Y; Zhang X
BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
[TBL] [Abstract][Full Text] [Related]
7. Cancer statistics, 2024.
Siegel RL; Giaquinto AN; Jemal A
CA Cancer J Clin; 2024; 74(1):12-49. PubMed ID: 38230766
[TBL] [Abstract][Full Text] [Related]
8. Sunvozertinib: First Approval.
Dhillon S
Drugs; 2023 Nov; 83(17):1629-1634. PubMed ID: 37962831
[TBL] [Abstract][Full Text] [Related]
9. Amivantamab plus Chemotherapy in NSCLC with
Zhou C; Tang KJ; Cho BC; Liu B; Paz-Ares L; Cheng S; Kitazono S; Thiagarajan M; Goldman JW; Sabari JK; Sanborn RE; Mansfield AS; Hung JY; Boyer M; Popat S; Mourão Dias J; Felip E; Majem M; Gumus M; Kim SW; Ono A; Xie J; Bhattacharya A; Agrawal T; Shreeve SM; Knoblauch RE; Park K; Girard N;
N Engl J Med; 2023 Nov; 389(22):2039-2051. PubMed ID: 37870976
[TBL] [Abstract][Full Text] [Related]
10. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 2.2023.
Ettinger DS; Wood DE; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; DeCamp M; Dilling TJ; Dowell J; Durm GA; Gettinger S; Grotz TE; Gubens MA; Hegde A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Ng T; Otterson GA; Patel SP; Patil T; Polanco PM; Riely GJ; Riess J; Schild SE; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory KM; Hughes M
J Natl Compr Canc Netw; 2023 Apr; 21(4):340-350. PubMed ID: 37015337
[TBL] [Abstract][Full Text] [Related]
11. TRUST-II: a global phase II study of taletrectinib in
Nagasaka M; Ohe Y; Zhou C; Choi CM; Yang N; Liu G; Felip E; Pérol M; Besse B; Nieva J; Raez L; Pennell NA; Dimou A; Marinis F; Ciardiello F; Seto T; Hu Z; Pan M; Wang W; Li S; Ou SI
Future Oncol; 2023 Jan; 19(2):123-135. PubMed ID: 36877099
[TBL] [Abstract][Full Text] [Related]
12. Targeting HER2-positive breast cancer: advances and future directions.
Swain SM; Shastry M; Hamilton E
Nat Rev Drug Discov; 2023 Feb; 22(2):101-126. PubMed ID: 36344672
[TBL] [Abstract][Full Text] [Related]
13. Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs?
Zhang SS; Ou SI
Lung Cancer (Auckl); 2022; 13():67-73. PubMed ID: 36317157
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
